2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2082

Presence of Acrocyanosis in Patients with Joint Hypermobility
Abstract Number: 2551

Presence of Germinal Centers at Baseline Is Associated with Clinical Response of Glandular Essdai Domain after Abatacept Treatment in Primary Sjogren’s Syndrome
Abstract Number: 1585

Presence of Swollen and Tender Joints in Patients Fulfilling Minimal Disease Activity Criteria
Abstract Number: 1805

Prevalence and Associating Factors with Atypical Femoral Fractures: An Asian Single Center Based Case-Control Study
Abstract Number: 390

Prevalence and Correlates of Patient-Physician Discordance in Early Rheumatoid Arthritis
Abstract Number: 2441

Prevalence and Determinants of Treatment Adherence Among Patients with Rheumatoid Arthritis
Abstract Number: 2720

Prevalence and Features of Metabolic Syndrome in Systemic Sclerosis
Abstract Number: 1388

Prevalence and Predictive Factors of Drug-Free and Sustained Remission in Patients with Early Arthritis
Abstract Number: 2640

Prevalence and Predictors of ECG Cardiovascular Abnormalities in Lupus Patients
Abstract Number: 1650

Prevalence and Prognostic Implications of IgG4 in Membranous Lupus Nephritis
Abstract Number: 1079

Prevalence of Cardiac Arrhythmias in Systemic Lupus Erythematosus
Abstract Number: 1372

Prevalence of Cardiovascular Disease in US Veterans with Rheumatoid Arthritis and Hepatitis C Infection
Abstract Number: 1550

Prevalence of Enthesitis and Dactylitis, Impact on Disease Severity and Evolution over 12 Months in Psa Patients Treated with Anti-TNF in a Real-World Setting
Abstract Number: 165

Prevalence of Gout in the Adult Population of France in 2013
Abstract Number: 2023

Prevalence of Inflammatory Arthritis Conditions in the First Nations Population of Alberta

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].